GW Pharmaceuticals has received Orphan Drug designation from the FDA for Epidiolex. The candidate contains plant-derived Cannabidiol (CBD) as its active ingredient, and is being tested for use in treating children with Dravet syndrome, a rare and severe form of infantile-onset, genetic, drug-resistant epilepsy syndrome. Epidiolex is an oral liquid formulation of a highly purified extract of CBD, a non-psychoactive molecule from the cannabis plant. Following receipt of this orphan designation, G...